The Phase III Glass-Art trial is designed to determine the survival benefit derived from, and safety of, adding Neuradiab to the current standard of care therapy, consisting of surgery, radiation and adjuvant chemotherapy (temozolomide), for patients diagnosed with primary glioblastoma mulitforme.
The randomized trial will enroll up to 760 patients at leading treatment centers across the US.
Alan Ezrin, president and CEO of Bradmer, said: “We look forward to bringing this investigational drug to patients via collaborative efforts with more than 30 US cancer centers that are participating in the Glass-Art trial.”